For the first time, somebody asked the question directly — and 2,719 women with lipedema answered. Here is what the survey found, what a survey can and cannot prove, and how to hold both at once in clinic.
LF
Primary source Srinivasan A, Kartt J, Cochrane JC, et al. Lipedema Foundation · Obesity Pillars, 2026
Why this matters
1st
The first study to examine GLP-1 and GLP-1/GIP receptor agonist use in people with lipedema. Before this, the entire clinical literature was a five-patient case series.
Srinivasan A et al., Obesity Pillars, 2026;100316
Read this first. This is a patient-reported survey, not a randomized trial. It cannot prove that GLP-1 medications improve lipedema. What it can do — and what good science does with a question nobody has studied — is establish that the signal is real enough, and large enough, to be worth testing properly. That is the honest frame for everything below.
Core Concepts
Six things to understand before you answer this question for a patient.
Click any card for a quick reference summary with key pearls and references.
01
First of Its Kind
What the study actually was, who answered it, and why nothing like it existed before 2026.
Read pearls
02
What the Survey Found
PROMIS health scores, pain, swelling, and function — current users versus never-users.
Read pearls
03
Why It Might Work
Inflammation, fibrosis, and lymphatic congestion — the biology that makes this plausible.
Read pearls
04
How to Read a Survey
Where surveys mislead, where they earn their keep, and how a question becomes a trial.
Read pearls
05
What I'm Seeing in Clinic
My own observation, clearly labeled as observation — and why it doesn't count as evidence.
Read pearls
06
Lipedema Is Not Obesity
They co-occur and get conflated constantly. The distinction changes the treatment target.
Read pearls
Clinical Walkthroughs
Two conversations that deserve a full screen.
These open dedicated walkthroughs with step-by-step reasoning.
Is This Lipedema?
Separating lipedema from obesity and from lymphedema, step by step. You cannot answer the GLP-1 question until you've answered this one.
Open walkthrough
Considering a GLP-1 in Lipedema
How to set expectations, what to measure at baseline, what counts as a response — and where this evidence actually sits on the ladder.
Open walkthrough
Sources
Primary source: Srinivasan A, Kartt J, Daftuar F, Harmacek LD, Samouhos E, Galia S, Heil S, Clark E, Mascio C, Cochrane JC. GLP-1 and GLP-1/GIP receptor agonist medication use and self-reported outcomes in individuals with lipedema: Results from a large online survey. Obesity Pillars. 2026;100316. doi:10.1016/j.obpill.2026.100316 — Foundation-initiated research, Lipedema Foundation.
Background source: Matthew Carmody, MD, DABOM & Leslyn Keith, OTD, CLT. Lipedema and Obesity: Distinct Diagnoses, Distinct Care. Obesity Medicine 2026 — The Heart of Obesity Care.
This is a teaching summary. GLP-1 and GLP-1/GIP receptor agonists are not FDA-approved for lipedema. For clinical decisions, consult the primary literature and current guidelines.
GLP-1s & Lipedema / Is This Lipedema?
Clinical Walkthrough
Is This Lipedema — or Obesity, or Lymphedema?
Lipedema is a clinical diagnosis. There is no lab, no imaging study, no biopsy that makes it. Click each step to expand the reasoning.
01Look at the distribution — and the feet
+
Lipedema fat is bilateral, symmetrical, and disproportionate: the lower body is dramatically out of proportion to the trunk. Arms are involved in a substantial minority.
The tell: feet and hands are spared, producing an abrupt cuff at the ankle or wrist. Lymphedema does not spare the foot.
02Ask about pain — specifically, pain to touch
+
Pain is not a bonus feature of lipedema; it is a required one. Ask about tenderness to light pressure, easy bruising, and a heavy or aching quality that worsens through the day.
Uncomplicated obesity does not produce fat that hurts when you pinch it. If there is no pain, question the diagnosis.
03Take the weight history
+
The signature history is a patient who has lost weight — sometimes a great deal, sometimes surgically — and watched the upper body change while the legs did not.
Onset or worsening clustered around puberty, pregnancy, or menopause supports a hormone-sensitive process. Bariatric surgery does not alter lipedema adipose tissue.
04Examine the tissue and rule out lymphedema
+
Feel for nodularity — the pebbled, granular texture within the subcutaneous fat. Note skin changes and any cuffing above the ankle.
Lymphedema: typically asymmetric, involves the foot, positive Stemmer sign, pitting early. Lipedema: symmetric, spares the foot, negative Stemmer, non-pitting early.
The two can coexist as lipo-lymphedema in later stages — finding one does not exclude the other.
05Apply the criteria, then stage separately
+
The Keith et al. framework requires female sex and pain as necessary features, alongside disproportionate limb fat, skin and tissue changes, and diet-unresponsiveness. All five present confirms the diagnosis.
Stage reflects tissue accumulation, not how much the patient suffers. Record symptom severity separately from stage — otherwise you will undertreat the Stage 1 patient in significant pain.
06Decide whether obesity is also present
+
This is the step that determines what you are treating. Many lipedema patients are more metabolically healthy than their body habitus suggests — unless obesity co-occurs, which it frequently does.
If both are present, you have two diagnoses with two sets of goals. Say which one the medication is for, and measure accordingly.
Final synthesis
Lipedema = female sex + pain + bilateral disproportionate limb fat sparing the feet + tissue changes + diet-resistance. Stage the tissue, score the symptoms, and name obesity separately if it's there.
References
Keith L et al. Lipedema diagnostic criteria framework. 2024.
Carmody M, Keith L. Lipedema and Obesity: Distinct Diagnoses, Distinct Care. Obesity Medicine 2026.
Dal'Forno-Dini T et al. An Bras Dermatol. 2026. doi:10.1016/j.abd.2025.501270
GLP-1s & Lipedema / Practical Framework
Practical Framework
Considering a GLP-1 in Lipedema
There is no guideline for this. What follows is a way to think about it honestly — with the patient, and with yourself.
+ Objective measures: pain on pinch, ultrasound fat thickness
– Five people. No control. Uncontrolled enthusiasm risk.
Tier 3 · This Survey
2,719 women, PROMIS-10 · Obesity Pillars 2026
+ Large, consistent, patient-centered outcomes
– Self-reported, cross-sectional, unblinded, confounded by weight loss
Tier 4 · Missing
Randomized controlled trial
+ Would answer the question
– Does not exist yet. This is the gap the survey exists to justify filling.
The conversation, step by step
01Name the indication you're actually treating
+
If the patient has obesity alongside lipedema, obesity is the on-label indication and the honest reason for the prescription. Roughly two-thirds of survey respondents were taking these medications for weight management.
Say it clearly: "I'm treating your obesity. There is early evidence your lipedema symptoms may also improve. That would be welcome, but it isn't what I'm promising."
02State the evidence honestly
+
Patients with lipedema have usually been dismissed, misdiagnosed, and sold things. Over-promising here does real damage.
The accurate sentence: "The first study on this came out in 2026. It surveyed almost 2,700 women and found those on these medications reported less pain, less swelling, and better function. It's a survey, not a trial, so it can't prove the medication caused that."
03Measure something before you start
+
Without a baseline you are relying on recall — the exact weakness that limits the survey. Document, at minimum:
• Pain score, including tenderness to pressure • Swelling and heaviness, and how they change through the day • A functional anchor: stairs, standing tolerance, walking distance • Limb measurements at fixed landmarks, if you can standardize them • Compression use and any change in it
04Give it a fair trial at a therapeutic dose
+
Judge response only after a therapeutic dose has been sustained for an adequate duration — the same discipline you apply to any obesity pharmacotherapy. Early timepoints during titration tell you very little.
Tirzepatide was the most commonly used agent among survey respondents, which likely reflects prescribing patterns rather than any demonstrated superiority in lipedema.
05Define response in the patient's terms
+
Percent weight loss is the wrong sole endpoint here. Lipedema fat is characteristically diet-resistant, so a patient can lose weight and see her legs barely change — and still have less pain.
Ask directly: does it hurt less, is it less heavy, can you do more? Those are the outcomes the survey moved, and they are the ones the patient came in for.
06Keep the rest of lipedema care running
+
A GLP-1 does not replace what already helps: compression, complete decongestive therapy, water-based exercise, carbohydrate-restricted eating patterns, and psychological support for a condition that has usually been dismissed for years.
Nutrition support matters especially here — adequate protein and attention to muscle mass during weight loss, since lipedema patients are already at risk for reduced function.
Practical pearl
Prescribe for the indication you can defend, measure the symptoms the patient cares about, and describe the evidence as what it is — a promising first signal that has not yet been proven. That combination lets you offer real hope without selling certainty you don't have.
References
Srinivasan A et al. Obesity Pillars. 2026;100316.
Patton L et al. Clin Pract. 2025;15(7):128.
Mohseni Y et al. Dermatol Surg. 2026. doi:10.1097/DSS.0000000000005172
Viana DPDC et al. Int J Mol Sci. 2025;26(21):10741.